Page 56 - Ipo Market

IPO subscriptions: Process only money-backed ASBA applications, says Sebi

Latest directive follows instances during LIC's IPO where certain applications had to be cancelled as they didn't have sufficient funds in bank accounts

Ethos debuts on a weak note; stock lists at 6% discount to issue price

Shares of Ethos listed at Rs 825, a 6 per cent discount when compard with its issue price of Rs 878 per share on the NSE.

Aether Industries' IPO subscribed 6.3 times on final day of offer

Aether's Rs 808-crore offering capped a busy month for IPOs, which saw a cumulative mop up of Rs 30,140 crore by eight companies

Aether Industries' Rs 800 crore IPO opens today. Should you subscribe?

Analysts believe that Aether's multiple chemistry competencies to use for a wide array of products makes it a distinguished market player compared to other chemical companies

Delhivery IPO's 3-day offer opens today: All you need to know

Delhivery provides supply chain solutions to a diverse base of 23,113 active customers such as e-commerce marketplace, direct-to-consumers e-tailers, and enterprises across several verticals.

IPO-bound Delhivery has promising growth potential: Samco Securities

The Indian logistics business is poised for tremendous expansion, and the IPO-bound Delhivery, with its focus on the fast-growing e-commerce market, has promising growth potential ahead of it

Decent debut for Campus Activewear; lists 22% higher against issue price

The stock opened at Rs 355, 22 per cent higher against issue price of Rs 292 on the BSE.

Russia-Ukraine crisis: IPO market grinds to a halt after a blockbuster 2021

Investment bankers say it will be challenging to launch even a single deal in March

Budget 2022, LIC IPO update can spark up to 11% rally in insurance stocks

Shares of the major private insurers, HDFC Life and ICICI Prudential are seen testing key support levels currently.

Medanta brand owner, Veeda Clinical get Sebi's go-ahead to float IPOs

Co-founded by Naresh Trehan, Medanta brand owner Global Health is a leading private multi-speciality tertiary care providers in the north and east regions of India

Nykaa, Paytm: Recent IPOs down 48% from 52-week high. Should you buy any?

Calendar year 2021 (CY21) was one of the most remarkable years for the primary markets where nearly Rs 1.2 trillion was mopped up till early December by 66 companies

Supriya Lifescience IPO subscribed 74 times on last day of share sale

Supriya Lifesciences had priced its IPO between Rs 265 and Rs 274 per share

UPI limit hike signals change in IPO allotment, to boost HNI participation

In November, more than 7.6 million UPI mandates were created for IPO applications

Hong Kong's IPO market withers as billion-dollar listings lapse

China's regulatory onslaught leads to slowdown in the hub's market

Liquidity moving away from China to high-growth nations: Sumit Jalan

Jalan says investor sentiment, hit by a spate of poor listings in August, shall improve as we see successful listing going ahead

Should you bid for loss-making Devyani International's Rs 1,800 crore IPO?

At the upper end of the price band, Devyani is offered at 9.5x market capitalisation/sales as per FY21 financial statement, compared to peers like Jubilant Foodworks (15x), Westlife Development (8.8x)

IPO market nears peak as valuations hit 20-yr high, analysts raise concern

Low interest rates, hefty returns have driven record demand for IPOs, but with valuations for newly public companies now at levels last seen during dot-com bubble, some analysts are raising concerns

Robinhood banks on its traders' allegiance in IPO like no other

Robinhood will reserve up to 35% of shares for its app users at the pre-trading range of $38 to $42 apiece

Shyam Metalics, Sona Comstar: What grey mkt is signalling ahead of listing

Shyam Metalics shares traded at a premium of Rs 123-125 or nearly 40 per cent over the issue price of Rs 306 in the grey market ahead of listing, while Sona Comstar shares were trading flat

Should you subscribe to India Pesticides IPO? Here's what analysts say

India Pesticides IPO: Analysts have largely assigned 'Subscribe' rating to the issue on the back of positive growth prospects, strong financials and reasonable valuations